Whalesbook
Financial Performance Surpasses Projections
Dr Reddy's Laboratories reported its financial results for the third quarter of fiscal year 2025 (ending December 31, 2024), revealing performance that surpassed market expectations. The company announced a consolidated revenue of ₹7,006 crore, marking a 4.4% increase compared to the same period last year, against an expectation of largely flat sales. Profitability also showed positive momentum, with profit after tax (PAT) rising by 12.6% to ₹1,377 crore. Furthermore, the company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 15% to ₹2,007 crore, indicating strong operational efficiency.
Segment Performance and Future Catalysts
The revenue growth was primarily driven by robust performance in key markets including India, Europe, and various emerging economies. This expansion helped offset certain headwinds observed in the U.S. business, which experienced lower contributions from legacy products such as Revlimid. Analysts anticipate that the U.S. business, excluding Revlimid, might see single-digit growth, while other geographic segments are projected to continue their double-digit expansion.
A significant focus for future growth is the company's pharmaceutical pipeline. Dr. Reddy's has received regulatory approval for semaglutide in India, with a targeted launch scheduled for March 21. Filings are underway for this product in approximately 80 global markets, and a review response has been submitted in Canada with a goal date of May 2026. Additionally, the company has filed the intravenous form of its abatacept biosimilar for review by the U.S. Food and Drug Administration (FDA). These developments are seen as potential key catalysts for future expansion.
Divided Analyst Sentiment and Market Outlook
Despite the strong quarterly results, analyst sentiment remains divided. Brokerage firm CLSA upgraded its rating to 'Hold' with a price target of ₹1,210, citing the positive beat on revenue and earnings. HSBC maintained a 'Buy' rating and a price target of ₹1,435, highlighting strong sales growth in India and Russia, alongside favorable foreign exchange benefits. Conversely, Citi reiterated a 'Sell' rating with a price target of ₹1,070, expressing concerns about the anticipated tapering of generic Revlimid revenues and potential pressure on earnings from increased future expenses, including higher SG&A and R&D spending. Overall, among 40 analysts tracking the company, 16 recommend 'Buy', 11 suggest 'Hold', and 13 advise 'Sell'.
Market Reaction and Valuation
On Thursday, January 22, 2026, shares of Dr Reddy's Laboratories were trading higher. The stock closed the previous trading day, Wednesday, January 21, 2026, at ₹1,156, and is down approximately 8% year-to-date. As of mid-morning on January 22, 2026, the stock was trading around ₹1,162.50 with a trading volume of approximately 1,250,000 shares. The company currently has a market capitalization of approximately ₹65,500 crore and a trailing twelve-month Price-to-Earnings (P/E) ratio of around 29.5x.
Peer Comparison
Dr Reddy's reported Q3 FY25 revenue growth of 4.4% and PAT growth of 12.6%. This performance occurred within a broader context of positive results from other major pharmaceutical companies. For example, Sun Pharmaceutical Industries reported its Q3 FY25 results, showing consolidated revenue increased by 10% and profit after tax grew by 17% for the same quarter, indicating a generally positive trend across the Indian pharmaceutical sector.